Display options
Cite
Griffioen M, van Bergen CA, Falkenburg JH. Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets. Front Immunol. 2016;7:100doi: 10.3389/fimmu.2016.00100.
Griffioen, M., van Bergen, C. A., & Falkenburg, J. H. (2016). Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets. Frontiers in immunology, 7100. https://doi.org/10.3389/fimmu.2016.00100
Griffioen, Marieke, et al. "Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets." Frontiers in immunology vol. 7 (2016): 100. doi: https://doi.org/10.3389/fimmu.2016.00100
Griffioen M, van Bergen CA, Falkenburg JH. Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets. Front Immunol. 2016 Mar 15;7:100. doi: 10.3389/fimmu.2016.00100. eCollection 2016. PMID: 27014279; PMCID: PMC4791598.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2016 Mar 15;7:100. doi: 10.3389/fimmu.2016.00100. eCollection 2016.

Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.

Frontiers in immunology

Marieke Griffioen, Cornelis A M van Bergen, J H Frederik Falkenburg

Affiliations

  1. Department of Hematology, Leiden University Medical Center , Leiden , Netherlands.

PMID: 27014279 PMCID: PMC4791598 DOI: 10.3389/fimmu.2016.00100

Abstract

Allogeneic stem cell transplantation (alloSCT) can be a curative treatment for hematological malignancies. Unfortunately, the desired anti-tumor or graft-versus-leukemia (GvL) effect is often accompanied with undesired side effects against healthy tissues known as graft-versus-host disease (GvHD). After HLA-matched alloSCT, GvL and GvHD are both mediated by donor-derived T-cells recognizing polymorphic peptides presented by HLA surface molecules on patient cells. These polymorphic peptides or minor histocompatibility antigens (MiHA) are produced by genetic differences between patient and donor. Since polymorphic peptides may be useful targets to manipulate the balance between GvL and GvHD, the dominant repertoire of MiHA needs to be discovered. In this review, the diversity of autosomal MiHA characterized thus far as well as the various molecular mechanisms by which genetic variants create immune targets and the role of cryptic transcripts and proteins as antigen sources are described. The tissue distribution of MiHA as important factor in GvL and GvHD is considered as well as possibilities how hematopoietic MiHA can be used for immunotherapy to augment GvL after alloSCT. Although more MiHA are still needed for comprehensive understanding of the biology of GvL and GvHD and manipulation by immunotherapy, this review shows insight into the composition and kinetics of in vivo immune responses with respect to specificity, diversity, and frequency of specific T-cells and surface expression of HLA-peptide complexes and other (accessory) molecules on the target cell. A complex interplay between these factors and their environment ultimately determines the spectrum of clinical manifestations caused by immune responses after alloSCT.

Keywords: T-lymphocytes; allogeneic stem cell transplantation; donor lymphocyte infusion; graft-versus-host disease; graft-versus-leukemia reactivity; hematological malignancy; immunotherapy; minor histocompatibility antigens

References

  1. Front Immunol. 2014 Nov 06;5:529 - PubMed
  2. J Immunol. 2013 Apr 15;190(8):3869-77 - PubMed
  3. Hematology Am Soc Hematol Educ Program. 2011;2011:299-304 - PubMed
  4. Eur J Immunol. 2002 Oct;32(10):2748-58 - PubMed
  5. Nat Rev Immunol. 2007 May;7(5):340-52 - PubMed
  6. Leukemia. 2005 Jan;19(1):83-90 - PubMed
  7. J Clin Invest. 2005 Dec;115(12):3506-16 - PubMed
  8. Nat Rev Immunol. 2011 Nov 11;11(12):823-36 - PubMed
  9. Immunol Cell Biol. 2011 Mar;89(3):396-407 - PubMed
  10. Hematol J. 2003;4(5):315-20 - PubMed
  11. Leukemia. 2013 Mar;27(3):642-9 - PubMed
  12. Clin Cancer Res. 2008 Aug 15;14(16):5260-9 - PubMed
  13. Blood. 1999 Aug 15;94(4):1201-8 - PubMed
  14. Ann Med. 2014 Sep;46(6):384-96 - PubMed
  15. Cancer Immunol Immunother. 2008 Jun;57(6):849-57 - PubMed
  16. Cytometry A. 2008 Nov;73(11):1043-9 - PubMed
  17. Nat Med. 2002 Apr;8(4):410-4 - PubMed
  18. Clin Exp Immunol. 2011 Jan;163(1):1-10 - PubMed
  19. J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87 - PubMed
  20. Haematologica. 2014 Dec;99(12):1854-9 - PubMed
  21. Blood. 2009 Oct 22;114(17 ):3684-92 - PubMed
  22. Science. 1995 Jun 9;268(5216):1476-80 - PubMed
  23. J Exp Med. 2008 Nov 24;205(12):2863-72 - PubMed
  24. Blood. 2007 Jan 1;109(1):365-73 - PubMed
  25. Biol Blood Marrow Transplant. 2012 Sep;18(9):1353-67 - PubMed
  26. Cancer Res. 2010 Nov 15;70(22):9073-83 - PubMed
  27. EMBO Rep. 2015 Dec;16(12 ):1640-55 - PubMed
  28. PLoS One. 2011;6(8):e23217 - PubMed
  29. Blood. 2008 Mar 15;111(6):3286-94 - PubMed
  30. Haematologica. 2007 Jan;92(1):72-80 - PubMed
  31. Science. 2006 Sep 8;313(5792):1444-7 - PubMed
  32. Blood. 2002 Dec 1;100(12):3877-86 - PubMed
  33. J Exp Med. 2001 Jan 15;193(2):195-206 - PubMed
  34. Haematologica. 2012 Aug;97(8):1196-204 - PubMed
  35. Bone Marrow Transplant. 2006 Jun;37(12):1129-34 - PubMed
  36. J Exp Med. 2003 Jun 2;197(11):1489-500 - PubMed
  37. Blood. 2010 May 13;115(19):3869-78 - PubMed
  38. Biol Blood Marrow Transplant. 2015 Jun;21(6):1000-7 - PubMed
  39. Best Pract Res Clin Haematol. 2008 Sep;21(3):543-57 - PubMed
  40. Blood. 1990 Feb 1;75(3):555-62 - PubMed
  41. Nat Rev Immunol. 2014 Jun;14(6):377-91 - PubMed
  42. Blood. 2008 Dec 1;112(12):4371-83 - PubMed
  43. Blood. 2007 Aug 1;110(3):1055-63 - PubMed
  44. Haematologica. 2015 Oct;100(10):e419-22 - PubMed
  45. Leukemia. 2014 Nov;28(11):2235-40 - PubMed
  46. Blood. 1991 Oct 15;78(8):2120-30 - PubMed
  47. Lancet. 2009 May 2;373(9674):1550-61 - PubMed
  48. Cancer Treat Rev. 2010 Nov;36(7):528-38 - PubMed
  49. Exp Hematol. 2003 Sep;31(9):743-51 - PubMed
  50. Immunol Res. 2008;41(1):56-78 - PubMed
  51. Blood. 2003 Jul 15;102(2):621-9 - PubMed
  52. J Immunol. 2002 Sep 15;169(6):3131-6 - PubMed
  53. Nat Med. 1999 Jul;5(7):839-42 - PubMed
  54. J Exp Med. 2003 May 19;197(10):1279-89 - PubMed
  55. PLoS One. 2014 Jan 15;9(1):e85198 - PubMed
  56. Haematologica. 2012 Aug;97(8):1205-8 - PubMed
  57. Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3837-42 - PubMed
  58. PLoS One. 2011;6(6):e21266 - PubMed
  59. Science. 1998 Feb 13;279(5353):1054-7 - PubMed
  60. Nat Rev Immunol. 2015 Apr;15(4):203-16 - PubMed
  61. Mol Cell Proteomics. 2015 Mar;14(3):658-73 - PubMed
  62. J Immunol. 2001 Sep 15;167(6):3223-30 - PubMed
  63. Blood. 2010 Jun 10;115(23):4923-33 - PubMed
  64. Clin Cancer Res. 2015 May 1;21(9):2177-86 - PubMed
  65. Expert Rev Hematol. 2014 Oct;7(5):671-81 - PubMed
  66. Science. 2015 Apr 3;348(6230):69-74 - PubMed
  67. PLoS One. 2011;6(6):e21699 - PubMed
  68. Tissue Antigens. 2014 Oct;84(4):374-60 - PubMed
  69. Blood. 2007 May 1;109(9):4089-96 - PubMed
  70. Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S33-8 - PubMed
  71. Blood. 2006 Jun 15;107(12):4954-60 - PubMed
  72. J Exp Med. 1999 Jan 18;189(2):301-8 - PubMed
  73. Br J Haematol. 2006 Aug;134(4):406-16 - PubMed
  74. Clin Cancer Res. 2009 Dec 1;15(23):7137-43 - PubMed
  75. Blood. 2013 Sep 12;122(11):1863-72 - PubMed
  76. Blood. 2012 Oct 4;120(14):2796-806 - PubMed
  77. Blood. 2013 Sep 12;122(11):1963-73 - PubMed
  78. J Immunother. 2009 Jul-Aug;32(6):539-51 - PubMed
  79. J Clin Med. 2015 Mar 19;4(3):488-503 - PubMed
  80. Blood. 2009 May 21;113(21):5041-8 - PubMed
  81. J Leukoc Biol. 2014 Apr;95(4):551-62 - PubMed
  82. Blood. 2006 May 1;107(9):3779-86 - PubMed
  83. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7 - PubMed
  84. Cytotherapy. 2008;10(2):108-15 - PubMed

Publication Types